Close
Symposium Spotlight: Biomarkers in MND – improving drug development and clinical trial design

Symposium Spotlight: Biomarkers in MND – improving drug development and clinical trial design

Reading Time: 4 minutes Diagnosing disease faster, accurately predicting disease progression, assessing the ability of a new drug to reach its target – I think we’d all agree that these three things are essential requirements for treating all diseases. But how can we achieve this? The answer may lie in biomarkers. In his plenary talk at last year’s International…

Identifying potential new diagnostic biomarkers in the blood

Reading Time: 6 minutes Guest researcher blog post about the recently published paper on the identification of potential new biomarkers in the blood, in the journal Brain Communications. Written by lead author, Dr Greig Joilin, Postdoctoral Research Fellow at the University of Sussex: Diagnosis of MND is currently a time-consuming process of elimination, causing patients and families prolonged stress…

Tissue biomarkers: Highlights from Glasgow

Reading Time: 3 minutes This blog is part of the ‘Highlights from Glasgow’ collection of articles, where you can read about the content of some of the talks and posters presented at the 29th International Symposium on ALS/MND. Around the globe, teams are working to find tissue biomarkers for MND and there some promising candidates coming through, some of…

Developing the Biomarkers in Oxford Project

Reading Time: 2 minutes Biomarkers in Oxford (BioMOx) is a research project with the aim of identifying a diagnostic biomarker for MND, which could be used to track the progression of this condition. What are biomarkers? The aim is to identify biomarkers, or ‘biological fingerprints’ for MND. This could be through testing blood and spinal fluid (CSF) samples from…

Why we need biomarkers

Reading Time: 3 minutes Yesterday’s announcement by the biotechnology company Trophos SA of the lack of effectiveness of their compound olesoxime adds to the long list of drugs that have failed to live up to their early promise in the lab. It’s a story that’s common across the world of neurodegenerative disease, including common conditions such as Parkinson’s disease…

VALOR Biogen’s Tofersen trial: a look at the open label extension data

VALOR Biogen’s Tofersen trial: a look at the open label extension data

Reading Time: 6 minutes The Motor Neurone Disease Association are pleased to discuss the additional results from the Biogen phase 3 clinical trial of Tofersen which were presented at the 20th European Network for the Cure of Amyotrophic Lateral Sclerosis (ENCALS) meeting in Edinburgh, Scotland, on the 1-3rd of June 2022. Tofersen is a type of potential treatment known…